Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
Roshan PK, Assistant Professor, Emergency Physician at Government Medical College, posted on LinkedIn:
”Breaking Down Pulmonary Embolism (PE) Treatment by Risk Level
From the 2022 NEJM Review on Pulmonary Embolism – a comprehensive guide by Kahn and de Wit:
Low-Risk PE (Stable, no RV strain or elevated biomarkers):
• Start with oral anticoagulants like apixaban (10mg 2x/day for 7 days, then 5mg 2x/day) or rivaroxaban.
• Outpatient treatment often safe if no other concerns.
• No thrombolysis or embolectomy needed.
• Duration: At least 3 months; longer if high recurrence risk.
Intermediate-Risk PE (Stable but with RV dysfunction or high biomarkers):
• Immediate low-molecular-weight heparin (LMWH) for anticoagulation.
• Hospital monitoring essential – watch for worsening.
• Thrombolysis only if deteriorating (systemic preferred; catheter-directed as alternative).
• Embolectomy if high bleeding risk or near-shock.
• Same duration as low-risk.
High-Risk PE (Unstable with hypotension/shock):
• IV unfractionated heparin + reperfusion therapy.
• Systemic thrombolysis first if no high bleeding risk.
• Surgical or catheter-directed embolectomy if thrombolysis contraindicated or fails.
• Urgent action to stabilize
Remember, risk stratification uses hemodynamics, imaging, and biomarkers. Always seek professional medical advice – this is for info only.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies